NIH Is Sitting on More Than $1 Billion It Must Obligate by September 30 — Which Is About to Compress a Year of Awards Into 90 Days

Most of the coverage of the 2026 research-funding crisis has focused on what is not happening: new NIH awards down more than 50 percent year-over-year, peer-review panels canceled, advisory councils postponed, a phantom pipeline of forecasts that never convert into funding opportunities. All of that is real. But there is a second half to the story that far fewer grant seekers are preparing for, and it is arguably more actionable: the money that has not gone out still has to.

NIH received a congressional appropriation for Fiscal Year 2026. Barring a rescission, that money is not optional — federal agencies operate under a use-it-or-lose-it obligation rule, and unobligated balances of one-year appropriations generally expire at the end of the fiscal year. The fiscal year ends September 30. As of early spring, NIH had approved roughly 1,900 new and competitive grants from October through late March — fewer than half its normal pace — and had fallen about $1 billion behind its typical timeline for awarding new grants. That is not money that has been canceled. In most cases it is money that has been delayed. And delayed appropriated dollars, as any veteran grants administrator will tell you, do not vanish quietly in September. They get spent in a rush.

Why a year-end cliff is coming

The federal budget cycle has a hard architecture. Congress appropriates for a fiscal year; the agency must obligate the funds within that year or, for most grant accounts, forfeit them back to the Treasury. Agencies are institutionally allergic to forfeiting money — an unspent balance is politically indefensible and invites next year's appropriators to cut the account. So the structural incentive at every federal grantmaking agency is to get to zero, or close to it, by September 30.

In a normal year, NIH smooths its awards across all twelve months, and the fourth quarter carries a modest bump. 2026 is not a normal year. The agency spent the first half of the year far below pace because of layered political review, staff losses from layoffs and early retirements, a fall government shutdown that pushed review meetings back by months, and a new computational screening step that scans proposals for flagged terms. The mechanical consequence is arithmetic: if roughly the full appropriation must be obligated by September 30, and only a fraction went out in the first three quarters, then a disproportionate share has to be pushed out the door in the final quarter. A year of grantmaking is being compressed toward a 90-day window.

This is the paradox at the center of 2026 research funding. The same administrative friction that made the first half historically slow creates the conditions for an unusually concentrated year-end surge — assuming the money is obligated rather than left to lapse or be clawed back. That assumption is the risk, and we return to it below.

Who is positioned to catch the surge

A compressed obligation window does not reward everyone equally. It rewards the applications that are already through review and sitting in a fundable position — the ones an agency can obligate quickly without new panels, new councils, or new process. Concretely, that favors:

• Applications with a fundable score already in hand. If your R01 or R21 has been scored and is near or within the payline, you are exactly the kind of award an agency reaches for when it needs to move money fast. Council concurrence and just-in-time documentation should be locked and ready.
• Non-competing continuations and supplements. Renewing an existing award or adding an administrative or competitive supplement is procedurally lighter than a new competing award. In a year-end rush, the path of least resistance gets funded.
• Programs and institutes that are behind their own spend plans. The institutes furthest from their obligation targets have the most money to move and the strongest incentive to move it. Knowing where your institute stands relative to its plan is genuine intelligence.
• Administratively clean applicants. Just-in-time requests answered instantly, human-subjects and animal-welfare approvals current, budgets that need no negotiation. Anything that adds days of back-and-forth is friction the agency cannot afford in September.

The corollary is uncomfortable but worth stating: a brilliant application that still needs a study section, a council meeting, and a round of revisions is not a Q4 candidate no matter how strong it is. The year-end surge rewards readiness over merit at the margin, because the binding constraint is time to obligate, not scientific quality.

What applicants should do right now

The practical playbook for the next 75 days is about removing every source of delay between a funding decision and an obligation.

Get your just-in-time material in before you are asked. Other Support pages current, IRB and IACUC approvals in hand, budget justifications clean. When a program officer is trying to obligate money in the final weeks of September, the application that answers in an hour beats the one that answers in a week.

Talk to your program officer — specifically about timing. The single most valuable question you can ask right now is not "will I be funded" but "where does this institute stand against its FY2026 spend plan, and what would help you move an award before September 30." Program staff under pressure to obligate are often more communicative in Q4 than at any other point in the cycle.

Have supplement and continuation requests drafted and ready to submit on short notice. If an institute finds itself with money to move and a short runway, an administrative supplement to an existing award is one of the fastest vehicles it has. Being the grantee with a shovel-ready, well-justified supplement request already written is a real advantage.

Do not let a strong new application sit unsubmitted waiting for a "better" cycle. In a normal year, timing your submission for an optimal council round is smart. In a year where the entire pipeline is congested and money must move, being in the queue and administratively clean beats waiting.

The real risk: obligation versus rescission

The strategy above rests on one load-bearing assumption — that the appropriated money will be obligated rather than allowed to lapse or be pulled back. That is not guaranteed. An administration that has slowed awards through process could, in principle, let balances expire, or Congress could rescind unobligated funds. The proposed rewrite of the government-wide grant rules — which would hand agencies expanded authority to withhold and terminate discretionary awards — sits directly on top of this question, and we cover its mechanics in depth in our analysis of the OMB Uniform Guidance overhaul.

So there are two scenarios, and a prepared applicant is positioned for both. If the money flows, the readiness playbook lets you catch a surge that unprepared competitors will miss. If the money is left to lapse, the same discipline — clean documentation, active program-officer relationships, diversified funding — is exactly what protects a lab through a lean year. There is no version of the next 75 days in which being obligation-ready hurts you.

The bottom line

The 2026 research-funding story is usually told as pure contraction, and for the first half of the year that framing was correct. But appropriated dollars have a deadline, and September 30 is coming. Whether NIH races to obligate its backlog or lets it expire, the applicants who win are the ones who are already scored, already documented, and already talking to the program officers who will be under the most pressure to move money in the final weeks of the fiscal year. The slow half of 2026 is behind us. The compressed half is what you can still prepare for. For the fuller picture of how the pipeline seized up in the first place, see our companion analysis, The Federal Funding Machine Is Broken.